Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival

Cancer Research

Volumn 72, Issue 3, 2012, Pages 747-756

  Robert, Francis ^a   Mills, John R ^a   Agenor, Aouod ^a   Wang, Dantong ^a   DiMarco, Sergio ^a   Cencic, Regina ^a   Tremblay, Michel L ^a,b   Gallouzi, Imed Eddine ^a,b   Hekimi, Siegfried ^a   Wing, Simon S ^a,c   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOHARRINGTONINE; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TSC1; RAPAMYCIN; TUBERIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA CACHEXIA SYNDROME; ARTICLE; CACHEXIA; CANCER REGRESSION; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DRUG TARGETING; LYMPHOMA; MALE; METABOLIC DISORDER; MOUSE; MUSCLE ATROPHY; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 84863048541     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2739     Document Type: Article

References (50)

1. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89:381-410.
2. DeWys WD. Diet and cancer prevention: an overview. Semin Oncol 1983;10:255-6. (Pubitemid 14167231)
3. Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, et al. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 2005;11: 5590-4. (Pubitemid 41060837)
4. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006;42:31-41. (Pubitemid 41814530)
5. Bibby MC, Double JA, Ali SA, Fearon KC, Brennan RA, Tisdale MJ. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 1987;78:539-46.
6. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47:5919-23. (Pubitemid 18018730)
7. Matsumoto T, Fujimoto-Ouchi K, Tamura S, Tanaka Y, Ishitsuka H. Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma. Br J Cancer 1999;79: 764-9. (Pubitemid 29082103)
8. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 2004;308: 929-34. (Pubitemid 38263967)
9. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64. (Pubitemid 41637985)
10. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136: 731-45.
11. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7. (Pubitemid 38418805)
12. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118:2651-60. (Pubitemid 351949792)
13. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318: 533-8. (Pubitemid 16173038)
14. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008;105:10853-8.
15. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR). Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
16. McLean JA, Tobin G. Animal and human calorimetry. Cambridge, UK: Cambridge University Press; 1987.
17. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8. (Pubitemid 33104839)
18. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001;98:14440-5. (Pubitemid 33121410)
19. Combaret L, Adegoke OA, Bedard N, Baracos V, Attaix D, Wing SS. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab 2005;288: E693-700. (Pubitemid 40397203)
20. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007;6:458-71. (Pubitemid 350163055)
21. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011;668 Suppl 1:S81-6.
22. Shibata M, Nezu T, Takekawa M, Takizawa H, Ando K, Miyake H, et al. Serum levels of interleukin-10 and interleukin-12 in patients with colorectal cancer. Ann N Y Acad Sci 1996;795:410-2. (Pubitemid 27029606)
23. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997;230:238-41. (Pubitemid 27211974)
24. Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordan RP. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993;92:2152-9. (Pubitemid 23333518)
25. Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996;67:849-55. (Pubitemid 26348815)
26. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-4.
27. Strassmann G, Jacob CO, Fong M, Bertolini DR. Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia. Cytokine 1993;5:463-8. (Pubitemid 24037682)
28. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011;6: e22538.
29. Lehle K, Birnbaum DE, Preuner JG. Predominant inhibition of interleukin- 6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. Transplant Proc 2005;37:159-61. (Pubitemid 40459722)
30. Simons JP, Schols AM, Campfield LA, Wouters EF, Saris WH. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 1997;93:273-7. (Pubitemid 27387066)
31. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer 2001;92:629-33. (Pubitemid 32735199)
32. Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999;126:744-9; discussion 749-50.
33. Hussain SN, Mofarrahi M, Sigala I, Kim HC, Vassilakopoulos T, Maltais F, et al. Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy. Am J Respir Crit Care Med 2010;182: 1377-86.
34. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004;101:2727-36. (Pubitemid 39603180)
35. Deans DA, Tan BH, Ross JA, Rose-Zerilli M, Wigmore SJ, Howell WM, et al. Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am J Clin Nutr 2009;89:1164-72.
36. Sun F, Sun Y, Yu Z, Zhang D, Zhang J, Song B, et al. Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population. Mol Diagn Ther 2010;14:95-100.
37. Sun F, Sun Y, Zhang D, Zhang J, Song B, Zheng H. Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. Ann Clin Lab Sci 2010;40:149-55.
38. Fujiki F, Mukaida N, Hirose K, Ishida H, Harada A, Ohno S, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997;57:94-9. (Pubitemid 27020335)
39. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to wholebody energy demands. Am J Clin Nutr 2009;89:1173-9.
40. Fearon KC. The Sir David Cuthbertson Medal Lecture. 1991. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992;51:251-65.
41. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, Saito H, et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer 1993;67:939-44. (Pubitemid 23147483)
42. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 1991;128:2657-9.
43. Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H, et al. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1995;1:1353-8.
44. Fujita J, Tsujinaka T, Ebisui C, Yano M, Shiozaki H, Katsume A, et al. Role of interleukin-6 in skeletal muscle protein breakdown and cathepsin activity in vivo. Eur Surg Res 1996;28:361-6. (Pubitemid 26305849)
45. Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992;148:3674-8.
46. Dhingra S, Bagchi AK, Ludke AL, Sharma AK, Singal PK. Akt Regulates IL-10 Mediated Suppression of TNFalpha-Induced Cardiomyocyte Apoptosis by Upregulating Stat3 Phosphorylation. PLoS One 2011;6:e25009.
47. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in Bcells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-8. (Pubitemid 34618857)
48. Cavarretta IT, Neuwirt H, Untergasser G,Moser PL, Zaki MH, Steiner H, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007;26:2822-32. (Pubitemid 46701444)
49. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21: 3232-7. (Pubitemid 350277750)
50. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43.